The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Randomized Phase III Trial of Whole-Abdominal Irradiation Versus Doxorubicin and Cisplatin Chemotherapy in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study
Open accessAbstract
Purpose: To compare whole-abdominal irradiation (WAI) and doxorubicin-cisplatin (AP) chemotherapy in women with stage III or IV endometrial carcinoma having a maximum of 2 cm of postoperative residual disease. Patients and Methods: Four hundred twenty-two patients were entered onto this trial. Of 396 assessable patients, 202 were randomly allocated to receive WAI, and 194 were allocated to receive AP. Irradiation dosage was 30 Gy in 20 fractions, with a 15-Gy boost. Chemotherapy consisted of doxorubicin 60 mg/m 2 and cisplatin 50 mg/m 2 every 3 weeks for seven cycles, followed by one cycle of cisplatin. Results: Most patient and tumor characteristics were well balanced. The median patient age was 63 years; 50% had endometrioid tumors. Median follow-up time was 74 months. The hazard ratio for progression adjusted for stage was 0.71 favoring AP (95% CI, 0.55 to 0.91; P < .01). At 60 months, 50% of patients receiving AP were predicted to be alive and disease free when adjusting for stage compared with 38% of patients receiving WAI. The stage-adjusted death hazard ratio was 0.68 (95% CI, 0.52 to 0.89; P < .01) favoring AP. Moreover, at 60 months and adjusting for stage, 55% of AP patients were predicted to be alive compared with 42% of WAI patients. Greater acute toxicity was seen with AP. Treatment probably contributed to the deaths of eight patients (4%) on the AP arm and five patients (2%) on the WAI arm. Conclusion: Chemotherapy with AP significantly improved progression-free and overall survival compared with WAI. Nevertheless, further advances in efficacy and reduction in toxicity are clearly needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
Jemal, A., Tiwari, R. C., Murray, T., Ghafoor, A., Samuels, A., Ward, E., Feuer, E. J., & Thun, M. J. (2004) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.54.1.8 · Cited by 3,984
Morrow, C. P., Bundy, B. N., Kurman, R. J., Creasman, W. T., Heller, P., Homesley, H. D., & Graham, J. E. (1991) · Gynecologic Oncology · doi:10.1016/0090-8258(91)90086-k · Cited by 1,285
Sample-Size Formula for the Proportional-Hazards Regression Model
Schoenfeld, D. A. (1983) · Biometrics · doi:10.2307/2531021 · Cited by 1,096
Thigpen, J. T., Brady, M. F., Homesley, H. D., Malfetano, J., DuBeshter, B., Burger, R. A., & Liao, S. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.088 · Cited by 390
Self-citationHoskins, P. J., Swenerton, K. D., Pike, J. A., Wong, F., Lim, P., Acquino-Parsons, C., & Lee, N. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.20.4048 · Cited by 275
Aapro, M. S., van Wijk, F. H., Bolis, G., Chevallier, B., van der Burg, M. E. L., Poveda, A., de Oliveira, C. F., Tumolo, S., Scotto di Palumbo, V., Piccart, M., et al. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg112 · Cited by 197
Thigpen, J. T., Blessing, J. A., Homesley, H. D., Creasman, W. T., & Sutton, G. P. (1989) · Gynecologic Oncology · doi:10.1016/0090-8258(89)90605-7 · Cited by 148
Self-citationComparison of clinical and surgical-staging in patients with endometrial carcinoma.
Cowles, T., Magrina, J. F., Masterson, B. J., & Capen, C. V. (1985) · PubMed · Cited by 128
Burke, T. W., Gershenson, D. M., Morris, M., Stringer, C. A., Levenback, C., Tortolero‐Luna, G., & Baker, V. V. (1994) · Gynecologic Oncology · doi:10.1006/gyno.1994.1245 · Cited by 88
Treatment of high-risk uterine cancer with whole abdominopelvic radiation therapy
Smith, R. S., Kapp, D. S., Chen, Q., & Teng, N. N. H. (2000) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(00)00724-0 · Cited by 72
The Significance of Adnexal Involvement in Endometrial Carcinoma
Connell, P. P., Rotmensch, J., Waggoner, S., & Mundt, A. J. (1999) · Gynecologic Oncology · doi:10.1006/gyno.1999.5415 · Cited by 72
The alpha spending function approach to interim data analyses
DeMets, D. L., & Lan, G. (1995) · Cancer Treatment and Research · doi:10.1007/978-1-4615-2009-2_1 · Cited by 58
Smith, M. R., Peters, W. A., & Drescher, C. W. (1994) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(94)70340-x · Cited by 58
DNA damage and cell killing cause and effect?
Elkind, M. M. (1985) · Cancer · doi:10.1002/1097-0142(19851115)56:10<2519::aid-cncr2820561033>3.0.co;2-m · Cited by 57
Stage III and stage IV endometrial carcinoma: A review of 41 cases
Pliskow, S., Peñalver, M., & Averette, H. E. (1990) · Gynecologic Oncology · doi:10.1016/0090-8258(90)90043-k · Cited by 39
Research works printed but not linked: 29
- 10.1006/gyno.1999.5569 · doi:10.1006/gyno.1999.5569
- 10.1016/0360-3016(91)90744-O · doi:10.1016/0360-3016(91)90744-o
- 10.1002/1097-0142(19930515)71:10<3076::AID-CNCR2820711030>3.0.CO;2-Z · doi:10.1002/1097-0142(19930515)71:10<3076::aid-cncr2820711030>3.0.co;2-z
- 10.1016/0360-3016(89)90948-6 · doi:10.1016/0360-3016(89)90948-6
- 10.1006/gyno.2000.5746 · doi:10.1006/gyno.2000.5746
- 10.1200/JCO.1994.12.7.1408 · doi:10.1200/jco.1994.12.7.1408
- 10.1006/gyno.1999.5444 · doi:10.1006/gyno.1999.5444
- 10.1006/gyno.2000.5827 · doi:10.1006/gyno.2000.5827
- 10.1046/j.1525-1438.1998.09892.x · doi:10.1046/j.1525-1438.1998.09892.x
- 10.1006/gyno.1996.0326 · doi:10.1006/gyno.1996.0326
- 10.1046/j.1525-1438.1998.09857.x · doi:10.1046/j.1525-1438.1998.09857.x
- 10.1016/S0360-3016(97)00581-6 · doi:10.1016/s0360-3016(97)00581-6
- 10.1002/(SICI)1097-0142(19960315)77:6<1115::AID-CNCR17>3.0.CO;2-4 · doi:10.1002/(sici)1097-0142(19960315)77:6<1115::aid-cncr17>3.0.co;2-4
- 10.1006/gyno.2002.6713 · doi:10.1006/gyno.2002.6713
- 10.1046/j.1525-1438.1999.99028.x · doi:10.1046/j.1525-1438.1999.99028.x
- 10.1006/gyno.2001.6278 · doi:10.1006/gyno.2001.6278
- 10.1016/0360-3016(89)90367-2 · doi:10.1016/0360-3016(89)90367-2
- 10.1006/gyno.2001.6189 · doi:10.1006/gyno.2001.6189
- 10.1002/1097-0142(19930601)71:11<3697::AID-CNCR2820711137>3.0.CO;2-U · doi:10.1002/1097-0142(19930601)71:11<3697::aid-cncr2820711137>3.0.co;2-u
- 10.1016/0090-8258(87)90229-0 · doi:10.1016/0090-8258(87)90229-0
- 10.1002/(SICI)1520-6823(1996)4:3<122::AID-ROI4>3.0.CO;2-# · doi:10.1002/(sici)1520-6823(1996)4:3<122::aid-roi4>3.0.co;2-#
- 10.1016/0360-3016(93)90276-2 · doi:10.1016/0360-3016(93)90276-2
- 10.1006/gyno.1997.4796 · doi:10.1006/gyno.1997.4796
- 10.1006/gyno.2001.6157 · doi:10.1006/gyno.2001.6157
- Corn BW, Lanciano RM, Greven KM, et al: Endometrial cancer with para-aortic adenopathy: Patterns of failure and opportunities for cure. Int J Radiat Oncol Biol Phys 24:223,1992-227, · doi:10.1016/0360-3016(92)90675-8
- 10.1016/0090-8258(87)90236-8 · doi:10.1016/0090-8258(87)90236-8
- 10.1016/0002-9378(86)90815-X · doi:10.1016/0002-9378(86)90815-x
- Rose PG, Cha SD, Tak WK, et al: Radiation therapy for surgically proven para-aortic node metastasis in endometrial carcinoma. Int J Radiat Oncol Biol Phys 24:229,1992-233, · doi:10.1016/0360-3016(92)90676-9
- 10.1038/bjc.1997.313 · doi:10.1038/bjc.1997.313
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Morice, P., Leary, A., Creutzberg, C., Abu-Rustum, N., & Darai, E. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00130-0 · Cited by 1,514
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
Colombo, N., Creutzberg, C., Amant, F., Bosse, T., González-Martín, A., Ledermann, J., Marth, C., Nout, R., Querleu, D., Mirza, M. R., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdv484 · Cited by 1,386
Walker, J. L., Piedmonte, M. R., Spirtos, N. M., Eisenkop, S. M., Schlaerth, J. B., Mannel, R. S., Spiegel, G., Barakat, R., Pearl, M. L., & Sharma, S. K. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.3248 · Cited by 1,288
Self-citationRossi, E. C., Kowalski, L. D., Scalici, J., Cantrell, L., Schuler, K., Hanna, R. K., Method, M., Ade, M., Ivanova, A., & Boggess, J. F. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30068-2 · Cited by 937
Metadata
- Authors
- Randall, M. E., Filiaci, V. L., Muss, H., Spirtos, N. M., Mannel, R. S., Fowler, J., Thigpen, J. T., & Benda, J. A.
- Venue
- Journal of Clinical Oncology
- Published
- 2006-01-01
- Volume
- 24
- Issue
- 1
- Pages
- 36-44
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2098960933
- Cited by
- 872
- References
- 20
- FWCI
- 37.39
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.